Unlock instant, AI-driven research and patent intelligence for your innovation.
Application of pseudolaric acid or derivatives thereof in preparation of medicines for preventing and treating ulcerative colitis
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for ulcerative colitis and hibiscus acetic acid, applied in the field of medicine, can solve the problems that the application of hibiscus acetic acid and its derivative HPB has not been reported yet
Inactive Publication Date: 2016-11-23
LOGISTICS UNIV OF CAPF
View PDF5 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0007] However, the application of hibiscusacetic acid and its derivative HPB in the preparation of drugs for the prevention and treatment of UC has not been reported so far.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0038] Example 1: The preventive and therapeutic effects of Tujin acetic acid and its derivative HPB on acute UC in mice
[0039] 1.1 Experimental materials:
[0040] 1.1.1 Experimental animals: clean-grade C57BL / 6 mice aged 8-9 weeks, purchased from Beijing Weitong Lihua Animal Laboratory Technology Co., Ltd. (Animal Certificate Number: SCXK-2012-001). The animals were repurchased and raised at 22℃±1℃, and they had free access to food and water.
[0041] 1.1.2 Reagents: DextranSodiumSulfate (DSS) relative molecular weight 36000~50,000 (American Sigma-Aldrich Company), Geoacetic acid and HPB (synthesized in our laboratory), positive controldrug: Prednisone (PDN, Tianjin Tianyao) Pharmaceutical Co., Ltd.), and other reagents are domestically pure.
[0068] Example 2: The preventive and therapeutic effects of kenya acetic acid and its derivative HPB on chronic UC in mice
[0069] 2.1 Experimental materials: the same as in Example 1.
[0070] 2.2 Experimental method:
[0071] 2.2.1 Establishment of animal model: the same as in Example 1.
[0072] 2.2.2 Grouping and administration method:
[0073] Prevention of chronic UC experiment, randomly divided into 5 groups, each group of 10, that is, normal control group, UC model group, Tujin acetic acid prevention group, HPB prevention group, PDN positive control group, the above-mentioned drugs Tujin acetic acid, HPB and PDN doses Both are 5mg / kg. The normal group was given free drinking water and regular feed. The model group was given 3% DSS distilled water solution for 7 consecutive days, and then given ordinary drinking water for 7 days (this is a cycle). A total of 3 cycles were induced to establish a chronic UC model, and the rate was 0.1mL / 10g body weight was given normal saline....
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses application of pseudolaric acid or derivatives thereof in preparation of medicines for preventing and treating ulcerative colitis. According to animal experiments on a mouse model suffering from human-like acute and chronic UC, the pseudolaric acid or derivatives HPB thereof in the invention can achieve the effects of restoring weight of mice suffering from UC and obviously reducing the diseaseactivity index, the pathological damage of colonic mucosa tissues is obviously improved, the content of proinflammatory factors such as TNF-alpha and IL-1beta is reduced, and the pseudolaric acid or derivatives HPB thereof have the effects of preventing and treating UC and can be used for developing medicines for preventing and treating UC.
Description
Technical field [0001] The present invention relates to the technical field of medicine, in particular to the application of kenya acetic acid and its derivative HPB in preparing medicines for preventing and treating ulcerative colitis. Background technique [0002] Ulcerative colitis (UC) is a chronic disease of unknown cause. The lesions are mostly located in the sigmoid colon and rectum, and can also extend to the descending colon or even the entire colon. Clinically, diarrhea, abdominal pain, mucus pus and blood in the stool, tenesmus are the main symptoms, and serious local (intestinal itself) and distant (systemic) complications can occur. The main pathological feature is diffuse tissue reaction, including ulcer formation, crypt abscess, small blood vesselinflammation, goblet cell reduction, and various types of inflammatory cell infiltration and other non-specific manifestations. UC is more common in young adults aged 20-40 in Europe and the United States, with an incide...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More